BMY
Bristol-Myers Squibb Co
NYSE · Pharmaceuticals
$61.99
+2.47 (+4.15%)
S&P 500
Large-Cap Stocks
Blue Chip Stocks
Pharmaceutical Stocks
Healthcare Stocks
Best Dividend Stocks
Highest Dividend Yield
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 48.12B | 47.43B | 47.69B | 47.91B | 45.13B |
| Net Income | 7.04B | 6.25B | 8.49B | 9.95B | 10.61B |
| EPS | — | — | — | — | — |
| Profit Margin | 14.6% | 13.9% | 17.8% | 20.8% | 23.5% |
| Rev Growth | +1.5% | +1.5% | -5.3% | +15.6% | -1.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 47.48B | 47.48B | 56.10B | 44.69B | 49.22B |
| Total Equity | 15.62B | 15.62B | 49.88B | 47.12B | 45.92B |
| D/E Ratio | 3.04 | 3.04 | 1.12 | 0.95 | 1.07 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 13.65B | 12.78B | 13.61B | 15.42B | 13.24B |
| Free Cash Flow | — | — | 5.93B | 6.08B | 6.45B |